close

Oculus Innovative Sciences, Inc., a biopharmaceutical company, together with its subsidiaries, develops, manufactures, and markets products based on Microcyn platform technology that intends to help prevent and treat infections in chronic and acute wounds. Its Microcyn platform technology, an oxychlorine small molecule formulation, treats various organisms that cause disease or pathogens, including viruses, fungi, and spores, as well as antibiotic resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus in wounds. The company offers Microcyn-based products primarily through its website, and various regional distributors in the United States. It sells its products to hospitals, physicians, and nurses; and other healthcare practitioners who are the caregivers to patients being treated for acute or chronic wounds, as well as those patients undergoing surgical procedures. The company was formerly known as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in August 2001. Oculus Innovative Sciences was incorporated in 1999 and is based in Petaluma, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.21
Volume	72859
Volume Avg	136662
52 Week High	2.20
52 Week Low	0.83
PE	N/A
PE (group average)	N/A
EPS Year	-0.27
EPS change Q/Q	-25%
EPS change Q/Q Yr ago	0%
EPS change Q/Q next Q est	-50%
EPS change Y/Y	-27.59%
REV change Q/Q	17.39%
REV change Q/Q Yr ago	22.73%
EPS next Q est	-0.04
EPS next Y est	-0.13
Divident Annual	0.00
Dividend Yield	0%